Nup98 Antibody (2H10): sc-101546

Nup98 Antibody (2H10) is a rat monoclonal IgG2c antibody that detects Nup98 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Nup98 is a crucial component of nuclear pore complexes (NPCs), which facilitate the bi-directional transport of macromolecules between the nucleus and cytoplasm, thereby playing a vital role in cellular communication and function. Anti-Nup98 antibody (2H10) recognizes a protein essential for multiple RNA export pathways, ensuring that mRNA and other RNA molecules are efficiently transported to the cytoplasm for translation. The NUP98 gene encodes precursor proteins that yield two nucleoplasmically oriented nucleoporins, Nup98 and Nup96, both of which are integral to the structure and function of NPCs. Notably, Nup98 is a member of the GLFG nucleoporin family and is characterized by the presence of O-linked N-acetylglucosamine moieties and a distinctive pentapeptide repeat (XFXFG). Nup98 plays a crucial role in developmental processes, as this protein is essential for gastrulation, a critical stage associated with rapid cell proliferation, while being dispensable for basal cell growth. Furthermore, the Nup98-HoxA9 fusion protein, resulting from the t(7;11)(p15;p15) translocation in acute myeloid leukemia, highlights Nup98′s role in leukemogenesis, potentially through the inhibition of HoxA9-mediated terminal differentiation and aberrant nucleocytoplasmic transport. Nup98 monoclonal antibody (2H10) serves as an invaluable tool for researchers studying nucleocytoplasmic transport, RNA export mechanisms, and the implications of Nup98 in various diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Nup98 Antibody (2H10) References:

1. NUP98 dysregulation in myeloid leukemogenesis.  |  Moore, MA., et al. 2007. Ann N Y Acad Sci. 1106: 114-42. PMID: 17442773
2. Nucleoplasmic Nup98 controls gene expression by regulating a DExH/D-box protein.  |  Capitanio, JS., et al. 2018. Nucleus. 9: 1-8. PMID: 28934014
3. p300 suppresses leukemia development in NUP98-HOXD13 driven myelodysplastic syndrome.  |  Man, N. and Nimer, SD. 2018. Oncotarget. 9: 26603-26604. PMID: 29928471
4. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.  |  Michmerhuizen, NL., et al. 2020. Blood. 136: 2275-2289. PMID: 32766874
5. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.  |  Heikamp, EB., et al. 2022. Blood. 139: 894-906. PMID: 34582559
6. Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation.  |  Chandra, B., et al. 2022. Cancer Discov. 12: 1152-1169. PMID: 34903620
7. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia.  |  Bertrums, EJM., et al. 2023. Haematologica. 108: 2044-2058. PMID: 36815378
8. The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.  |  Rasouli, M., et al. 2023. Hemasphere. 7: e935. PMID: 37520776
9. Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations.  |  Miao, H., et al. 2024. Leukemia. 38: 1674-1687. PMID: 38890447
10. NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML.  |  Heikamp, EB., et al. 2024. Cell Rep. 43: 114901. PMID: 39475509

The preferred Nup98 antibody is Nup98 Antibody (C-5): sc-74578.